Total Payments
$3,450
2024 Payments
$3,090
Companies
20
Transactions
84
Medicare Patients
3,199
Medicare Billing
$449,322
Payment Breakdown by Category
Consulting$1,836 (53.2%)
Food & Beverage$1,427 (41.4%)
Education$186.65 (5.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $1,836 | 1 | 53.2% |
| Food and Beverage | $1,427 | 81 | 41.4% |
| Education | $186.65 | 2 | 5.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $1,907 | 5 | $0 (2024) |
| GlaxoSmithKline, LLC. | $468.71 | 27 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $222.84 | 11 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $175.73 | 7 | $0 (2024) |
| Genentech USA, Inc. | $151.33 | 4 | $0 (2024) |
| Actelion Pharmaceuticals US, Inc. | $89.79 | 5 | $0 (2024) |
| HARMONY BIOSCIENCES LLC | $69.08 | 4 | $0 (2024) |
| Philips North America LLC | $59.85 | 3 | $0 (2024) |
| JAZZ PHARMACEUTICALS INC. | $51.84 | 3 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $36.29 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,090 | 69 | GENZYME CORPORATION ($1,887) |
| 2023 | $213.46 | 12 | GlaxoSmithKline, LLC. ($64.68) |
| 2021 | $26.88 | 1 | Actelion Pharmaceuticals US, Inc. ($26.88) |
| 2019 | $99.99 | 1 | Genentech USA, Inc. ($99.99) |
| 2017 | $19.71 | 1 | GlaxoSmithKline, LLC. ($19.71) |
All Payment Transactions
84 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Education | In-kind items and services | $86.66 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/11/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $17.55 | General |
| Category: IMMUNOLOGY | ||||||
| 12/09/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $16.95 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/25/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $18.86 | General |
| Category: Respiratory | ||||||
| 11/22/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $14.16 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/18/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Food and Beverage | In-kind items and services | $17.26 | General |
| Category: NEUROLOGY | ||||||
| 11/14/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $14.29 | General |
| Category: Respiratory | ||||||
| 11/13/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $9.19 | General |
| Category: RESPIRATORY | ||||||
| 11/01/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $15.73 | General |
| Category: Respiratory | ||||||
| 11/01/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $9.20 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/31/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $13.16 | General |
| Category: Immunology | ||||||
| 10/30/2024 | Genentech USA, Inc. | Xolair (Biological) | Food and Beverage | In-kind items and services | $17.29 | General |
| Category: Immunology | ||||||
| 10/28/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $20.91 | General |
| Category: Immunology | ||||||
| 10/25/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Food and Beverage | In-kind items and services | $18.84 | General |
| Category: NEUROLOGY | ||||||
| 10/24/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $0.52 | General |
| Category: RESPIRATORY | ||||||
| 10/23/2024 | Bayer Healthcare Pharmaceuticals Inc. | Adempas (Drug) | Food and Beverage | In-kind items and services | $18.50 | General |
| Category: Cardio-pulmonary | ||||||
| 10/23/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $12.71 | General |
| Category: RESPIRATORY | ||||||
| 10/18/2024 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $1,836.00 | General |
| 10/17/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $16.47 | General |
| Category: Respiratory | ||||||
| 10/16/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $13.11 | General |
| Category: Respiratory | ||||||
| 10/15/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Food and Beverage | In-kind items and services | $16.55 | General |
| Category: Cardiology | ||||||
| 10/03/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $13.16 | General |
| Category: RESPIRATORY | ||||||
| 10/02/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $0.53 | General |
| Category: RESPIRATORY | ||||||
| 09/26/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Food and Beverage | In-kind items and services | $13.72 | General |
| Category: Cardiology | ||||||
| 09/25/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $20.36 | General |
| Category: RESPIRATORY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 1,404 | 1,870 | $525,026 | $179,436 |
| 2022 | 15 | 983 | 1,332 | $348,894 | $125,937 |
| 2021 | 12 | 454 | 705 | $171,875 | $65,017 |
| 2020 | 9 | 358 | 708 | $209,335 | $78,933 |
Total Patients
3,199
Total Services
4,615
Medicare Billing
$449,322
Procedure Codes
62
All Medicare Procedures & Services
62 procedure records from CMS Medicare Utilization — Page 2 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 15 | 15 | $2,720 | $1,035 | 38.0% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2022 | 18 | 18 | $3,360 | $710.22 | 21.1% |
| 94726 | Test to determine lung volumes using sensors | Office | 2022 | 13 | 13 | $2,340 | $544.41 | 23.3% |
| 94618 | Test for exercise-induced lung stress | Office | 2022 | 15 | 15 | $1,710 | $381.17 | 22.3% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2022 | 12 | 12 | $2,400 | $248.71 | 10.4% |
| 94618 | Test for exercise-induced lung stress | Facility | 2022 | 20 | 20 | $1,600 | $114.54 | 7.2% |
| 94010 | Test to measure expiratory airflow and volume | Facility | 2022 | 19 | 19 | $570.00 | $49.49 | 8.7% |
| 94726 | Test to determine lung volumes using sensors | Facility | 2022 | 18 | 18 | $720.00 | $40.45 | 5.6% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Facility | 2022 | 15 | 15 | $750.00 | $35.28 | 4.7% |
| 94729 | Test to examine how well the lungs exchange gases | Facility | 2022 | 18 | 18 | $540.00 | $22.92 | 4.2% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 54 | 123 | $75,030 | $22,965 | 30.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 47 | 126 | $25,200 | $11,042 | 43.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 56 | 104 | $20,800 | $10,964 | 52.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 42 | 64 | $12,800 | $5,182 | 40.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 25 | 33 | $8,580 | $3,678 | 42.9% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 23 | 23 | $6,960 | $3,355 | 48.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 16 | 39 | $5,460 | $2,326 | 42.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 13 | 13 | $3,380 | $1,886 | 55.8% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 14 | 14 | $2,240 | $863.66 | 38.6% |
| 94729 | Measurement of lung diffusing capacity | Office | 2021 | 11 | 11 | $2,090 | $528.90 | 25.3% |
| 94726 | Determination of lung volumes using plethysmography | Office | 2021 | 11 | 11 | $1,980 | $515.67 | 26.0% |
| 94618 | Test for exercise-induced lung stress | Facility | 2021 | 26 | 26 | $2,055 | $499.46 | 24.3% |
| 94618 | Test for exercise-induced lung stress | Office | 2021 | 12 | 12 | $1,440 | $348.96 | 24.2% |
| 94010 | Measurement and graphic recording of total and timed exhaled air capacity | Facility | 2021 | 41 | 43 | $1,410 | $298.62 | 21.2% |
| 94726 | Determination of lung volumes using plethysmography | Facility | 2021 | 22 | 22 | $880.00 | $227.48 | 25.9% |
About Dr. Jonathan Galli, M.D
Dr. Jonathan Galli, M.D is a Pulmonary Disease healthcare provider based in Marlton, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/25/2011. The National Provider Identifier (NPI) number assigned to this provider is 1306139159.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jonathan Galli, M.D has received a total of $3,450 in payments from pharmaceutical and medical device companies, with $3,090 received in 2024. These payments were reported across 84 transactions from 20 companies. The most common payment nature is "Consulting Fee" ($1,836).
As a Medicare-enrolled provider, Galli has provided services to 3,199 Medicare beneficiaries, totaling 4,615 services with total Medicare billing of $449,322. Data is available for 4 years (2020–2023), covering 62 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Other Specialties Critical Care Medicine
- Location Marlton, NJ
- Active Since 05/25/2011
- Last Updated 10/15/2024
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1306139159
Products in Payments
- DUPIXENT (Biological) $247.19
- NUCALA (Biological) $213.06
- AREXVY (Drug) $140.47
- TRELEGY ELLIPTA (Drug) $115.18
- TEZSPIRE (Biological) $105.44
- Esbriet (Biological) $99.99
- UPTRAVI (Drug) $76.07
- WAKIX (Drug) $69.08
- (AK6) Vest Therapy (Device) $59.85
- AIRSUPRA (Drug) $58.51
- FASENRA (Biological) $58.40
- XYWAV (Drug) $51.84
- Xolair (Biological) $51.34
- Adempas (Drug) $35.50
- TYVASO (Drug) $32.31
- OFEV (Drug) $20.36
- Arikayce (Drug) $18.86
- LUNA (Device) $18.25
- LUMRYZ (Drug) $17.49
- RUCONEST (Biological) $16.51
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Marlton
Dr. Mark Weir, Mb Chb, MB CHB
Pulmonary Disease — Payments: $7,553
Pulmonary Disease $7,553
Dr. Eric Sztejman, Md, MD
Pulmonary Disease — Payments: $4,910
Pulmonary Disease $4,910
Dr. Emilio Mazza, Md, MD
Pulmonary Disease — Payments: $4,892
Pulmonary Disease $4,892
Allen Salm, Md, MD
Pulmonary Disease — Payments: $4,688
Pulmonary Disease $4,688
Abhishek Agarwal, Md, MD
Pulmonary Disease — Payments: $4,388
Pulmonary Disease $4,388
Matthew Gordon, Md, MD
Pulmonary Disease — Payments: $4,385
Pulmonary Disease $4,385